Next Article in Journal
An Estimation of Radiobiological Parameters for Head-and-Neck Cancer Cells and the Clinical Implications
Next Article in Special Issue
The Expression of Embryonic Liver Development Genes in Hepatitis C Induced Cirrhosis and Hepatocellular Carcinoma
Previous Article in Journal
The Stroma—A Key Regulator in Prostate Function and Malignancy
Previous Article in Special Issue
A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase
Cancers 2012, 4(2), 549-565; doi:10.3390/cancers4020549
Review

Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials

1
,
1
,
1
,
1
,
2
,
3
 and
1,*
1 Clinical Trials Unit, National Cancer Institute—“G. Pascale” Foundation, via Mariano Semmola, Napoli 80131, Italy 2 Medical Statistics, Second University, v. L. Armanni 5, Napoli 80138, Italy 3 Medical Oncology Unit, “G.Rummo” Hospital, Benevento 82100, Italy
* Author to whom correspondence should be addressed.
Received: 8 May 2012 / Revised: 25 May 2012 / Accepted: 30 May 2012 / Published: 5 June 2012
(This article belongs to the Special Issue Advances and Research Progress in Hepatocellular Carcinoma)
View Full-Text   |   Download PDF [163 KB, uploaded 5 June 2012]   |  

Abstract

No systemic therapy had been proven effective in patients with advanced hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated a clinically relevant prolongation of survival. Currently, sorafenib represents standard treatment for patients with advanced HCC and well-preserved liver function, whilst the evidence about its effectiveness in patients with more severe liver impairment is less robust. A randomized trial to demonstrate the efficacy of sorafenib in Child-Pugh B patients with advanced HCC is currently ongoing. In the meantime, several trials are testing the role of sorafenib in early HCC (as adjuvant treatment after potentially curative loco-regional therapies) and in intermediate stage (exploring different modalities of integration of sorafenib with trans-arterial chemo-embolization). The results of all these trials will better define the potentiality and the boundaries of use of sorafenib in HCC patients.
Keywords: hepatocellular carcinoma; sorafenib; Child-Pugh B patients; trans-arterial chemo-embolization hepatocellular carcinoma; sorafenib; Child-Pugh B patients; trans-arterial chemo-embolization
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
SciFeed

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
RIS
MDPI and ACS Style

Di Maio, M.; Daniele, G.; Piccirillo, M.C.; Giordano, P.; Signoriello, G.; Daniele, B.; Perrone, F. Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials. Cancers 2012, 4, 549-565.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert